2 completed, 2 recruiting, 2 unknown, 1 terminated. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 2, Recruiting 2, Unknown 2, Terminated 1 |
Follow Morphological and Microscopic Findings: new trials by email Literature Review of Morphological and Microscopic Findings trials Research Report on Morphological and Microscopic Findings
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimod Imiquimod, Loop Electrosurgical Excision Procedure - HSIL, High-Grade Squamous Intraepithelial Lesions, Vaginal Microbiome | Phase 4 | Recruiting | Barretos Cancer Hospital | 96 | 2024-04-02 | 2025-02-05 |
| Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR) Glizigen, Placebo - Papilloma Viral Infection, CIN1 | Phase 4 | Unknown | Catalysis SL | 120 | 2023-06-07 | 2024-02-07 |
| A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV) Nonavalent HPV vaccine (9vHPV/Gardasil-9™). - Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections | Phase 4 | Recruiting | Miquel Angel Pavon Ribas | 69 | 2022-09-13 | 2026-02-23 |
| "Lactobacillus Crispatus M247, LSIL and Microbiota" Lactobacillus Crispatus M247 - Vaginal Flora Imbalance, ASC-US | Phase 4 | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 90 | 2021-06-16 | 2023-04-11 |
| V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) V501 - Cervical Cancer, Cervical Intraepithelial Neoplasia | Phase 4 | Completed | Merck Sharp & Dohme LLC | 1030 | 2011-11-25 | 2018-11-28 |
| Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip PDT prior to Mohs surgery - Actinic Cheilitis, Squamous Cell Carcinoma In-situ (SCC-is) | Phase 4 | Completed | Tufts Medical Center | 34 | 2009-07-01 | 2011-07-06 |
| TRUST Study: Raptiva ® in Hand & Foot Psoriasis Efalizumab - anti CD11a recombinant human monoclonal antibody, Placebo - Chronic Plaque Psoriasis | Phase 4 | Terminated | Merck KGaA, Darmstadt, Germany | 76 | 2008-04-01 | 2014-02-27 |
Papillomavirus Infections (3) · Squamous Intraepithelial Lesions (3) · Uterine Cervical Neoplasms (2) · Actinic cheilitis (1) · Adenocarcinoma in Situ (1) · Atypical Squamous Cells of the Cervix (1) · Carcinoma, Squamous Cell (1) · Infections (1) · Margins of Excision (1) · Squamous Intraepithelial Lesions of the Cervix (1) · Uterine Cervical Dysplasia (1)
Pathological Conditions, Signs and Symptoms (7) · Genital Diseases (4) · Neoplasms (4) · Urogenital Diseases (4) · Communicable Diseases (3) · DNA Virus Infections (3) · Disease Attributes (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases, Female (3) · Pathologic Processes (3) · Precancerous Conditions (3) · Sexually Transmitted Diseases (3) · Sexually Transmitted Diseases, Viral (3)
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1) · Imiquimod (1)
Barretos Cancer Hospital (1) · Catalysis SL (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Merck KGaA, Darmstadt, Germany (1) · Merck Sharp & Dohme LLC (1) · Miquel Angel Pavon Ribas (1) · Tufts Medical Center (1)
Spain (2) · Austria (1) · Brazil (1) · Italy (1) · United States (1)
Gary Rogers, M.D. (1) · Nicole Selenko-Gebauer, MD (1)
2015 (1)